Close Menu

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray today initiated coverage of cancer diagnostics firm OncoCyte with an Overweight rating and a $6 target on the company's stock.

In a research note, analyst William Quirk said that in his view OncoCyte's test, called DetermaVu, is potentially best in class for lung cancer diagnosis, and he believes the US Centers for Medicare & Medicaid Services could start reimbursing for the test as early as late 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.